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Abstract
We present the case of a 9-year-old child with lysinuric protein intolerance and Fanconi syndrome.
She was referred to our hospital with a persistent metabolic acidosis and polyuria. Renal investiga-
tions revealed all laboratory signs of Fanconi syndrome, with glucosuria, generalized aminoacidur-
ia, phosphaturia and severe hypercalciuria. The diagnosis of Fanconi syndrome was conﬁrmed by a
renal biopsy that showed extensive lesions of proximal tubular epithelial cells with vacuolation of
these cells and a sloughing of the brush border.
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Introduction
Lysinuric protein intolerance (LPI; OMIM 222700) is a rare
autosomal recessive multiorgan disorder in which the
renal and intestinal transport of the cationic amino acids
lysine, arginine and ornithine is defective [1]. The molecu-
lar defect resides in mutations of the SLC7A7 gene, encod-
ing for y+ LAT-1, the catalytic light chain subunit of a
complex belonging to the heterodimeric amino acid trans-
porter family [2]. The basolateral transport defect is ex-
pressed in the epithelial cells of the intestine and the
kidney tubules, hepatocytes and skin ﬁbroblasts [3],
leading to a depletion of their tissue pools and, as a con-
sequence, to impaired functioning of the hepatic urea
cycle with hyperammonaemic episodes (Figure 1). Most,
but not all, of the symptoms of LPI have been linked to a
secondary urea cycle derangement due to impaired trans-
port of cationic amino acids. Typically, symptoms begin
after weaning with refusal of feeding, vomiting and conse-
quent failure to thrive. Hepatosplenomegaly, haemato-
logical anomalies and neurological involvement, including
hyperammonaemic coma, are recurrent clinical features
[4, 5]. Two major complications, pulmonary alveolar pro-
teinosis and renal disease, are increasingly observed in LPI
patients [5, 6]. The disease has long been erroneously
considered relatively benign when appropriately treated
with low-protein diet and L-citrulline supplementation.
During the past years, however, other manifestations have
suggested that LPI is not only a urea cycle disorder, but
also a complex multisystem disease with an uncertain
outcome [7], thus considerably modifying the way to view
this disorder.
We describe the clinical course in a patient with LPI and
renal pathology.
Case report
The patient was diagnosed with LPI at the 7 years of
age; she was born to consanguineous (ﬁrst-cousin)
healthy parents after three abortions. The patient had a
brother who died at the age of 6 years of respiratory
failure; he was diagnosed with mucopolysaccharidosis
because of the ﬁndings of delayed psychomotor develop-
ment, anorexia, repeated episodes of acute bronchitis,
hepatosplenomegaly and pancytopenia. At 6 years, our
patient presented signs and symptoms similar to those
observed in her brother: in particular, she was hospitalized
because of delayed psychomotor development, vomiting
and mild hepatosplenomegaly. The family history and
clinical features suggested a diagnosis of metabolic
disease that was then investigated. Complete blood count
showed that mild pancytopenia, renal and hepatic func-
tions were normal, lactate was 2.5 mmol/L (normal
<2 mmol/L), plasma ammonia was 194 mmol/L (normal
<70 mmol/L), ferritin was 103 mmol/L (normal 2–59
mmol/L) and LDH was 1180 U/L (normal 26–534 U/L). LPI
was diagnosed based on the ﬁndings of reduced plasma
ornithine, arginine and lysine, and of an increase in their
urinary levels. The ﬁnal proof of a defect in the SLC7A7
amino acid transporter was given by the ﬁnding of a
homozygous c.726G>A mutation in the patient’s DNA [8],
responsible for the premature termination of the protein
at aminoacid 242. Subsequently, she was put on a
protein-restricted diet (0.7–1.2 g/kg per day) and L-citrul-
line supplementation (100 mg/kg per day), and in the
following 2 years her clinical condition remained stable
and the plasma ammonia levels were in the normal
range. Then, at the age of 9, a persistent metabolic
acidosis (pH 7.33, pCO2 28 mmHg and bicarbonate
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14 mmol/L) with an elevated anion gap of 20.4 (normal
<15) was observed, and the patient was referred to our
hospital. Plasma organic acids were normal. Furthermore,
the patient presented polyuria (diuresis >3000 mL/day)
and renal investigations revealed all laboratory signs of
Fanconi syndrome, with glucosuria, generalized aminoaci-
duria, phosphaturia and severe hypercalciuria (Table 1).
The glomerular ﬁltration rate, evaluated by the creati-
nine clearance (Schwartz equation), was 88 mL/min per
1.73 m2 (normal 80–120). Echosonography of the kidney
was normal.
To explain the combination of a renal Fanconi syndrome
and elevated levels of organic acids in the urine, a renal
biopsy was performed after parental informed consent
had been obtained. Consistent with the existence of a
Fanconi syndrome, renal biopsy showed extensive lesions
of proximal tubular epithelial cells with a dramatic vac-
uolation of these cells and a sloughing of the brush
border. No evidence of immune deposits was shown by
immunoﬂuorescence (Figure 2).
Discussion
Renal involvement is a well-known manifestation of LPI.
However, its progressive characteristic has recently been
emphasized [9]. Most of the patients present with mild
proteinuria and microscopic haematuria for years with-
out overt consequences. However, some patients have
Fig. 1. Pathway for the disposal of nitrogen waste products in the urea cycle. Each number represents the following enzymes: 1, carbamylphosphate
synthetase; 2, ornithine carbamyltransferase; 3, argininosuccinate synthetase; 4, argininosuccinate lyase; 5, arginase; 6, N-acetylglutamate synthetase.
CoA, co-enzyme A; NH3, ammonia.
Table 1. Laboratory data on admission
Normal range Patient
Serum potassium (mEq/L) 3.6–5.0 3.3
Serum phosphorus (mg/dL) 2.5–4.3 2.6
Serum uric acid (mg/dL) 2.5–7.5 2.1
Serum chloride (mEq/L) 101–109 83
Serum bicarbonate (mmol/L) 22.0–26.0 14
Anion gap (mEq/L) 12 ± 3 20.4
Proteinuria Negative (−) (+)
Urinary pH 4.8–7.5 6.5
Urinary glucose Negative (−) (3+)










glomerular dysfunction due to mild glomerulonephritis,
whereas others display signs of Fanconi syndrome [9, 10].
Renal involvement may sometimes progress to end-stage
renal disease requiring dialysis and renal transplantation
[9]. Our patient had evidence of a full-blown Fanconi syn-
drome with proximal tubular acidosis. Besides a proximal
tubular acidosis, other signs of a complex tubular disorder
were found, i.e. diminished renal reabsorption of phosphate
[11], glucose, amino acids and carnitine. The majority of
cases of proximal renal tubular acidosis ﬁt into the category
of generalized tubule dysfunction with the Fanconi syn-
drome. This defect can be due either to backleak of solutes
via the paracellular pathway or to a generalized disorder
of the apical membrane and its transporters, a disorder
of the basolateral Na+, K+-ATPase or a metabolic disorder
that lowers ATP concentration. Electron microscopy of renal
tissue showed severe abnormalities in the ultrastructure of
proximal tubular apical membranes. We suggest that this is
the basic disorder causing proximal tubular dysfunction,
either through a diminished resorptive area and decreased
availability of transport proteins or through increased back-
leak of solutes from the proximal tubular cell. The cause of
the ultrastructural changes remains to be determined; pos-
sible mechanisms are a direct toxic effect of retainedmeta-
bolites on the cell membrane or a generalized disorder in
cellular energymetabolism [5].
The hypothesis that the accumulation of intracellular
lysine in the proximal tubule because of diminished basolat-
eral transport might exercise a cytotoxic effect leading
to renal tubular damage [12] has been confuted by the
evidence that patients with hyperlysinaemia due to other
diseases (i.e. 2-aminoadipic semialdehyde synthetase deﬁ-
ciency), with a similar heavy load on the renal tubular y+
LAT-1 system, never develop a renal Fanconi syndrome [13].
Therefore, we consider the intratubular accumulation of
lysine an unlikely candidate for the development of the
renal Fanconi syndrome.
It is known that, in LPI, there is a speciﬁc defect of
dibasic aminoacid transport, located at the basolateral
membrane of epithelial cells. However, this defect does
not cause disturbances in other basolateral transport
systems, such as Na+ and K+-ATPase. It is therefore not
likely that it would be the cause of the Fanconi syndrome.
In conclusion, this case demonstrates a rapid develop-
ment of a Fanconi syndrome in a child with LPI. The exist-
ence and possible cytotoxic effect of intracellular lysine
accumulation in proximal tubular cells deserve further
attention.
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Fig. 2. Light microscopy shows proximal tubules with vacuolated
cytoplasm and brush border attenuation.
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